Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris [PDF]
, 2019 The enigmatic yeast Candida auris has emerged over the last decade and rapidly penetrated our consciousness. The global threat from this multidrug-resistant yeast has generated a call to arms from within the medical mycology community.
Kean, Ryan, Ramage, Gordon
core +2 more sources
Antifungal resistance, combinations and pipeline: oh my!
Drugs in Context, 2023 Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically, Candida was responsible for approximately 15% of all nosocomial bloodstream infections.
Kayla R Stover +4 more
doaj +1 more source
Antifungal chemotherapies and immunotherapies for the future
Parasite Immunology, Volume 45, Issue 2, February 2023., 2023 Abstract Human fungal pathogens cause a broad plethora of infections, spanning cutaneous dermatophytoses to invasive infections in immunocompromised hosts. As eukaryotic pathogens are capable of morphotype switching, they present unique challenges both for drug development and the immunological response.
Darius Armstrong‐James
wiley +1 more source
Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
Journal of Women's Health, 2022 Background: Ibrexafungerp is a novel antifungal treatment for acute vulvovaginal candidiasis (VVC). Using pooled data from two phase three studies (VANISH 303 and 306) in the treatment of acute VVC, this analysis sought to determine the effectiveness of ibrexafungerp in various patient subgroups that may impact outcomes.
Oluwatosin Goje +10 more
openalex +3 more sources
Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin [PDF]
, 2023 Introduction: Invasive Candida Infections (ICIs) have undergone a series of significant epidemiological, pathophysiological, and clinical changes during the last decades, with a shift toward non-albicans species, an increase in the rate of exogenous ...
De Rosa, Francesco Giuseppe +1 more
core +8 more sources
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Journal of Fungi, 2022 The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel +5 more
doaj +1 more source
Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]
F1000Research, 2022 Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics.
Samantha E. Jacobs +2 more
doaj +1 more source
Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting? [PDF]
, 2022 The study of the pharmacological properties of an antifungal agent integrates the drug pharmacokinetics, the fungal growth inhibition, the fungicidal effect and the postantifungal activity, laying the basis to guide optimal dosing regimen selection.
Eraso, Elena +5 more
core +2 more sources
Ibrexafungerp: A novel oral glucan synthase inhibitor
Medical Mycology, 2019 AbstractIbrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp.
M R, Davis +2 more
openaire +2 more sources
Synthesis and Application of Bioactive N‐Functionalized Aziridines
Angewandte Chemie, Volume 137, Issue 44, October 27, 2025.This review discusses modern synthetic methods for the preparation of aziridine‐containing small molecules, including biocatalytic, electrocatalytic, and photocatalytic strategies. We highlight the compatibility of various synthetic methods with control of the exocyclic N‐substituent.
Hao Tan +4 more
wiley +2 more sources